UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 324

Sortiert nach

Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A

The New England journal of medicine, 2020-01, Vol.382 (1), p.29-40

2020

Volltextzugriff (PDF)

AAV5–Factor VIII Gene Transfer in Severe Hemophilia A

The New England journal of medicine, 2017-12, Vol.377 (26), p.2519-2530

2017

Volltextzugriff (PDF)

Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A

Nature medicine, 2022-04, Vol.28 (4), p.789-797

2022

Volltextzugriff (PDF)

Activity of transgene-produced B-domain–deleted factor VIII in human plasma following AAV5 gene therapy

Blood, 2020-11, Vol.136 (22), p.2524-2534

2020

Volltextzugriff (PDF)

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy

The New England journal of medicine, 2017-08, Vol.377 (9), p.819-828

2017

Volltextzugriff (PDF)

Functional definition and characterization of acute traumatic coagulopathy

Critical care medicine, 2011-12, Vol.39 (12), p.2652-2658

2011

Volltextzugriff (PDF)

Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A

Thrombosis and haemostasis, 2015-10, Vol.114 (4), p.804

2015

Volltextzugriff (PDF)

Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19

The New England journal of medicine, 2020-07, Vol.383 (3), p.288-290

2020

Volltextzugriff (PDF)

Clinical Considerations for Capsid Choice in the Development of Liver-Targeted AAV-Based Gene Transfer

Molecular therapy. Methods & clinical development, 2019-12, Vol.15, p.170-178

2019

Volltextzugriff (PDF)

Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A

The New England journal of medicine, 2020-01, Vol.382 (1), p.29

2020

Volltextzugriff (PDF)

Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A

The New England journal of medicine, 2022-03, Vol.386 (11), p.1013-1025

2022

Volltextzugriff (PDF)

Lupus Anticoagulant in Patients with Covid-19. Reply

The New England journal of medicine, 2020-11, Vol.383 (19), p.1893-1894

2020

Volltextzugriff (PDF)

Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies

Research and practice in thrombosis and haemostasis, 2022-07, Vol.6 (5), p.e12760-n/a, Article e12760

2022

Volltextzugriff (PDF)

Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-11, Vol.27 (6), p.947-956

2021

Volltextzugriff (PDF)

Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates

British journal of haematology, 2015-01, Vol.168 (1), p.113-123

2015

Volltextzugriff (PDF)

Hemophilia gene therapy knowledge and perceptions: Results of an international survey

Research and practice in thrombosis and haemostasis, 2020-05, Vol.4 (4), p.644-651

2020

Volltextzugriff (PDF)

Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort

Journal of thrombosis and haemostasis, 2021-06, Vol.19 (6), p.1436-1446

2021

Volltextzugriff (PDF)

Recombinant factor VIII Fc for the treatment of haemophilia A

European journal of haematology, 2021-06, Vol.106 (6), p.745-761

2021

Volltextzugriff (PDF)

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study

Haemophilia : the official journal of the World Federation of Hemophilia, 2020-05, Vol.26 (3), p.494-502

2020

Volltextzugriff (PDF)

Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIIIFc individualized prophylaxis: post hoc analysis from the A-LONG study

Therapeutic advances in hematology, 2022-02, Vol.13, p.20406207221079482-20406207221079482

2022

Volltextzugriff (PDF)

Evolution of haemophilia integrated care in the era of gene therapy: Treatment centre’s readiness in United States and EU

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-07, Vol.27 (4), p.511-514

2021

Volltextzugriff (PDF)

Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program

Therapeutic Advances in Hematology, 2019, Vol.10, p.2040620719858471-2040620719858471

2019

Volltextzugriff (PDF)

The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B

Blood, 2005-01, Vol.105 (2), p.518-525

2005

Volltextzugriff (PDF)

Haemophilias A and B

The Lancet (British edition), 2003-05, Vol.361 (9371), p.1801-1809

2003

Volltextzugriff (PDF)

1 – 25 von 324

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(304)
Mit Volltextzugriff
(287)

Publikationsform

Sprache

Englisch
(324)
Japanisch
(51)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(209)
Life Sciences & Biomedicine
(187)
Humans
(154)
Male
(73)
Biological And Medical Sciences
(68)
Female
(65)
Medical Sciences
(64)
Hematology
(57)
Middle Aged
(49)
Adult
(47)
Oncology
(37)
Mutation
(33)
Aged
(31)
Hemophilia
(30)
Animals
(27)
Lung Neoplasms - Genetics
(27)
Hematologic And Hematopoietic Diseases
(24)
Adolescent
(22)
Lung Neoplasms - Drug Therapy
(21)
Carcinoma, Non-Small-Cell Lung - Genetics
(20)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A

AAV5–Factor VIII Gene Transfer in Severe Hemophilia A

Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A

Activity of transgene-produced B-domain–deleted factor VIII in human plasma following AAV5 gene therapy

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy

Functional definition and characterization of acute traumatic coagulopathy

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A

Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A

Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19

Clinical Considerations for Capsid Choice in the Development of Liver-Targeted AAV-Based Gene Transfer

Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A

Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A

Lupus Anticoagulant in Patients with Covid-19. Reply

Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies

Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A

Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates

Hemophilia gene therapy knowledge and perceptions: Results of an international survey

Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort

Recombinant factor VIII Fc for the treatment of haemophilia A

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study

Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIIIFc individualized prophylaxis: post hoc analysis from the A-LONG study

Evolution of haemophilia integrated care in the era of gene therapy: Treatment centre’s readiness in United States and EU

Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program

The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B

Haemophilias A and B

Suchergebnisse filtern